Choice of TKIs in the first-line setting. (A) Percentage of low-risk patients. (B) Percentage of intermediate- plus high-risk patients. The indications of 50 panel members for the choice of the TKI in the first-line setting, according to age and to ELTS risk, in the absence of strong contraindications to dasatinib or nilotinib, are shown. The numbers over the bars express the proportion of panel members who have assigned priority to each TKI, respectively. With 1 exception (>80 years, low risk), the total of the numbers over the columns is higher than 100% because several panel members indicated >1 TKI. Some panel members also included bosutinib, although data and experience with bosutinib are still limited. A consensus for 2GTKIs (dasatinib or nilotinib) was reached in all young patients (18-40 years old) and in intermediate- plus high-risk adult patients (41-65 years old). A consensus for imatinib was reached in low-risk elderly patients (66-80 years old) and in all very elderly patients (>80 years old). No consensus was reached in intermediate- plus high-risk adult (41-65 years old) and elderly patients (66-80 years old). Low-risk patients account for ∼10%, 30%, 15%, and 4% in each age group, whereas intermediate- and high-risk patients account for ∼6%, 20%, 10%, and 3%, respectively, in each age group. Notice that the 2013 ELN recommendations did not assign any priority to any TKI. Also, the 1.2019 NCCN guidelines did not assign any priority as far as low-risk patients are concerned, irrespective of age, but suggested some priority for 2GTKIs, including bosutinib, in high- and intermediate-risk ones, not elderly.